JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial

Annals of Internal Medicine +

|

November 1, 1979

|

November 1, 1979

Related Experiment Videos

Contact us if these videos are not relevant.

View abstract on PubMed

Summary

This summary is machine-generated.

This study vaccinated 12 renal-transplant candidates with a live cytomegalovirus (CMV) vaccine before transplant. The vaccine successfully induced immunity, with most recipients retaining functioning kidneys and the vaccine strain not reactivating post-transplant.

Area Of Science

  • * Immunology
  • * Transplantation Medicine
  • * Virology

Background

  • * Primary cytomegalovirus (CMV) infections pose significant risks, including morbidity and mortality, to renal-transplant recipients.
  • * Establishing pre-transplant immunity to CMV is a critical unmet need in preventing post-transplant complications.

Purpose Of The Study

  • * To assess the safety and immunogenicity of a live human cytomegalovirus (Towne 125 strain) vaccine in seronegative renal-transplant candidates.
  • * To evaluate the potential for the vaccine strain to establish latency and reactivate after transplantation.

Main Methods

  • * Twelve seronegative renal-transplant candidates were vaccinated with the live human cytomegalovirus Towne 125 strain.
  • * Participants were monitored for adverse reactions before transplantation.
  • * Immunological responses (seroconversion, cellular immunity) were assessed, and vaccinees underwent transplantation, with post-transplant follow-up and viral DNA analysis.

Main Results

  • * The live CMV vaccine was well-tolerated, with only local reactions at the inoculation site.
  • * All vaccinees achieved seroconversion, and a CMV-specific cellular immune response was detected.
  • * Eight of ten transplanted vaccinees maintained functioning allografts up to one year; viral isolates post-transplant differed from the vaccine strain, suggesting no reactivation.

Conclusions

  • * Pre-transplant vaccination with live human cytomegalovirus (Towne 125) is safe and effective in inducing protective immunity in renal-transplant candidates.
  • * The vaccine strain did not appear to establish latency or reactivate post-transplantation, reducing the risk of CMV disease.
  • * This vaccination strategy holds promise for improving outcomes in renal-transplant recipients by mitigating CMV-related complications.

Related Experiment Videos

Contact us if these videos are not relevant.

Related Concept Videos